Article
Immunology
Kurt Brassington, Peter Kanellakis, Anh Cao, Ban-Hock Toh, Karlheinz Peter, Alex Bobik, Tin Kyaw
Summary: Research shows that the interaction between cardiac cytotoxic memory CD8+ T cells and overly stressed cardiomyocytes plays a crucial role in the development of non-ischemic hypertensive cardiac fibrosis. Inhibiting the activation of CD8+ T cells may be a promising therapeutic strategy for limiting hypertensive cardiac fibrosis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yao Wang, Xiaoyue Xu, Jacqueline E. Marshall, Muxue Gong, Yang Zhao, Kamal Dua, Philip M. Hansbro, Jincheng Xu, Gang Liu
Summary: HAPLN1 is downregulated in CRC patients, and it controls collagen deposition through the TGF-beta signaling pathway to regulate tumor growth. Therefore, increasing HAPLN1 levels may be a novel therapeutic option for CRC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Marija Mojic, Kiyomi Shitaoka, Chikako Ohshima, Sisca Ucche, Fulian Lyu, Hiroshi Hamana, Hideaki Tahara, Hiroyuki Kishi, Yoshihiro Hayakawa
Summary: By analyzing the immunological status of tumor antigen-specific CD8(+) T cells during tumor progression, it was found that NKG2D can control the fate and TOX expression of tumor-reacting CD8(+) T cells.
Review
Immunology
Baode Chen, Chenglin Mu, Zhiwei Zhang, Xuelin He, Xia Liu
Summary: Since its recognition as an essential cytokine in embryogenesis and tissue homeostasis, our understanding of the role of TGF-beta in mammalian development and disease, especially cancer, has been constantly updated. TGF-beta acts as the principal regulator of the immune system, but strengthening its signaling can limit immune response. The love-hate relationship between TGF-beta signaling and the immune system poses challenges in developing effective monotherapies, but recent studies on combination therapies have shown promising outcomes in cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Satu Salmi, Kaisla Halinen, Anton Lin, Sanna Suikkanen, Otto Jokelainen, Eija Rahunen, Hanna Siiskonen, Sanna Pasonen-Seppanen
Summary: In melanoma, CD8+ and GrB+ lymphocytes were found to be more abundant in pT4 melanomas and lymph node metastases compared to primaries. A low GrB/CD8 ratio was associated with better recurrence-free survival in primary melanomas, suggesting that GrB+ lymphocytes may represent activated immunosuppressive lymphocytes.
Article
Immunology
Nicolas Cermakian, Nathalie Labrecque
Summary: Most aspects of physiology, including immunity, exhibit 24-hour variations called circadian rhythms. CD8(+) T cells express circadian clock genes and present circadian oscillations in their transcriptome. CD8(+) T cell counts in blood and lymphoid organs show 24-hour rhythms, dependent on the cell's clock and hormonal rhythms. The circadian rhythms of CD8(+) T cells play an important role in fighting intracellular infections and have implications for cancer treatment and immunotherapy optimization.
JOURNAL OF IMMUNOLOGY
(2023)
Review
Immunology
Heleen H. Van Acker, Shixin Ma, Tommaso Scolaro, Susan M. Kaech, Massimiliano Mazzone
Summary: In the tumor microenvironment, CD8+ T cells face competition for metabolic resources from cancer cells, leading to impaired epigenetic mechanisms and functional limitations. This study discusses the impact of glucose/amino acid deficiency and elevated ROS levels in the TME on DNA methylation and histone modifications in CD8+ T cells, as well as the translational potential of epigenetic interventions to enhance current immunotherapeutic strategies.
TRENDS IN IMMUNOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Hao Tian, Wenxi Li, Guohao Wang, Ye Tian, Jie Yan, Songtao Zhou, Xinying Yu, Bei Li, Yunlu Dai
Summary: Intratumoral CD8(+) T cells play a crucial role in cancer immunotherapy, but the immunosuppressive tumor microenvironment (TME) limits their function and infiltration. Drug repurposing has identified existing drugs as immune modulators to improve TME immunosuppression and reactivate T-cell-mediated antitumor immunity. However, the suboptimal availability of these drugs in tumors hampers their full immunomodulatory potential. Self-degradable PMI nanogels carrying repurposed immune modulators (imiquimod and metformin) are developed for TME-responsive drug release. They remodel the TME by promoting dendritic cell maturation, repolarizing M2-like tumor-associated macrophages, and downregulating PD-L1 expression. Ultimately, the PMI nanogels reshape the immunosuppressive TME and efficiently enhance CD8(+) T cell infiltration and activation. These results suggest that PMI nanogels could be an effective combination drug with anti-PD-1 antibodies to enhance antitumor immune responses.
Article
Immunology
Zhifeng Zhou, Jieyu Li, Jingwen Hong, Shuping Chen, Mingshui Chen, Ling Wang, Wansong Lin, Yunbin Ye
Summary: This study introduces IL-15 and CCL19 into NKG2D-based CARs to generate 15x19 CAR T cells, which show higher cytotoxicity to gastric cancer cells, produce elevated levels of IL-15 and CCL-19, and exhibit improved T cell chemotaxis and reduced expression of T cell exhaustion markers. The 15x19 CAR T cells are effective in shrinking gastric cancer xenograft tumors and monitoring cancer in local and metastatic sites.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Niclas C. Blessin, Wenchao Li, Tim Mandelkow, Hannah L. Jansen, Cheng Yang, Jonas B. Raedler, Ronald Simon, Franziska Buscheck, David Dum, Andreas M. Luebke, Andrea Hinsch, Katharina Moller, Anne Menz, Christian Bernreuther, Patrick Lebok, Till Clauditz, Guido Sauter, Andreas Marx, Ria Uhlig, Waldemar Wilczak, Sarah Minner, Till Krech, Christoph Fraune, Doris Hoflmayer, Eike Burande, Stefan Steurer
Summary: Expansion of CD8(+) cytotoxic T lymphocytes plays a crucial role in anti-cancer immune activity, with varying impact on tumor prognosis depending on the tumor type. In colorectal and renal cell cancer, proliferating CD8(+) T cells are associated with favorable tumor parameters and prolonged overall survival, while in breast, ovarian, pancreatic and gastric cancer their role is not linked to clinicopathological data.
Article
Gastroenterology & Hepatology
Arata Itoh, David Adams, Wenting Huang, Yuehong Wu, Kritika Kachapati, Kyle J. Bednar, Patrick S. C. Leung, Weici Zhang, Richard A. Flavell, M. Eric Gershwin, William M. Ridgway
Summary: Enoxacin increases miRNA expression in dnTGF beta RII CD8 T cells, reduces the pathogenicity of CD8 T cells, and effectively stops the progression of autoimmune biliary disease. Targeting the miRNA pathway is a therapeutic approach to autoimmunity that corrects pathological miRNA abnormalities in autoreactive T cells.
Letter
Oncology
Chun-Ye Zhang, Shuai Liu, Ming Yang
Summary: Hepatocellular carcinoma is the most common type of liver cancer and a major cause of cancer-related death. Immunotherapy using CD8(+) T cells is effective for treating unresectable HCC, but these T cells often exhibit exhaustion phenotype. Amino acids or other nutrient metabolites in the tumor microenvironment play a crucial role in tumor growth and immune response.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Kuang Youlin, Liang Simin, Kang Jian, Zhang Li
Summary: This study found that pterostilbene can inhibit miR-20a expression in prostate cancer cells, thereby increasing the expression of antigen MICA/B and reducing the secretion of TGF-beta 1, promoting NK cell-mediated cytotoxicity against prostate cancer cells.
Article
Oncology
Jing Ge, Sheng-Lu Liu, Jing-Xiu Zheng, Yu Shi, Ying Shao, Yu-Jing Duan, Rui Huang, Li-Jun Yang, Tao Yang
Summary: ALKBH5 is poorly expressed in CRC, and overexpression of ALKBH5 attenuates CRC malignant progression by inhibiting CRC cell proliferation, migration, invasion and promoting CD8(+) T cells infiltration in the tumor microenvironment through NF-?B-CCL5 axis.
TRANSLATIONAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Agisilaos Balatsoukas, Filippo Rossignoli, Khalid Shah
Summary: NK cells, as innate lymphoid cells, have strong antitumor functions and can be used as therapeutic tools for brain malignancies. Despite being a minor fraction of immune cells in the brain, their role in CNS pathophysiology is gaining more attention. Enhancing the therapeutic potential of NK cells for primary and metastatic brain tumors requires exploring avenues to overcome the immunosuppressive microenvironment and tumor resistance mechanisms.
TRENDS IN MOLECULAR MEDICINE
(2022)
Review
Medicine, Research & Experimental
Joseph G. Taylor, Konstantinos Liapis, John G. Gribben
BIOMARKERS IN MEDICINE
(2015)
Editorial Material
Hematology
Joseph G. Taylor, Andrew Clear, Maria Calaminici, John G. Gribben
Letter
Hematology
Dimitris A. Tsitsikas, Susan Rowe, Alessandra Bosch, Caitlyn Hui, Nandini Sadasivam, Nicolaos J. Palaskas, Shivan Pancham, Syed Rizvi, Joseph Taylor, Paul Greaves, Andreas Glenthoj, Marianne Hoffmann, Emma Drasar, Perla Eleftheriou
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Joseph G. Taylor, Edward Truelove, Andrew Clear, Maria Calaminici, John G. Gribben
Summary: Classical Hodgkin lymphoma (CHL) is highly sensitive to PD1 inhibition, and PDL1 is expressed in CHL cells and tumor microenvironment. However, the correlation between PD1 expression and response to PD1 inhibitors is not observed, and there is no increase in cytotoxic markers after PD1 therapy. In contrast, elevated PDL1 expression predicts response to PD1 inhibitors and is associated with CHL MHC-II expression, TH recruitment, and enrichment of TH1 regulatory cells.
Article
Medicine, General & Internal
Marina Roy-Luzarraga, Tarek Abdel-Fatah, Louise E. Reynolds, Andrew Clear, Joseph G. Taylor, John G. Gribben, Stephen Chan, Louise Jones, Kairbaan Hodivala-Dilke
